OPDIVO QVANTIG FDA approval date

The FDA approved OPDIVO QVANTIG on 27 Dec 2024.

FDA approval date
27 Dec 2024

Drug identity has not yet been verified against registry records

Also recorded as HYALURONIDASE-NVHY; NIVOLUMAB

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2024-12-27DayOPDIVO QVANTIGFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761381", "applicant_as_listed_by_fda": "BRISTOL-MYERS SQUIBB", "brand_names": ["OPDIVO QVANTIG"], "active_ingredients": ["HYALURONIDASE-NVHY", "NIVOLUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20241227", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026